Cargando…
Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable‐drug‐naïve elderly or renal impaired patients with type 2 diabetes in the United States
AIM: To evaluate the effectiveness and tolerability of exenatide once weekly (EQW) compared with basal insulin (BI) among injectable‐drug‐naïve patients with type 2 diabetes mellitus (T2DM) who are elderly or have renal impairment (RI). MATERIALS AND METHODS: Initiators of EQW and BI with T2DM were...
Autores principales: | Loughlin, Anita M., Qiao, Qing, Nunes, Anthony P., Öhman, Peter, Ezzy, Stephen, Yochum, Laura, Clifford, C. Robin, Gately, Robert, Dore, David D., Seeger, John D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873410/ https://www.ncbi.nlm.nih.gov/pubmed/29193561 http://dx.doi.org/10.1111/dom.13175 |
Ejemplares similares
-
Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States
por: Loughlin, Anita M., et al.
Publicado: (2018) -
Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care
por: Nunes, Anthony P., et al.
Publicado: (2017) -
Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013) -
Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017) -
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)